lifespan.io – Join Us: Become a Lifespan Hero!
We are building public awareness and access to innovative treatments for controlling aging and age-related diseases!
- 61% Funded
- $3,066 per month
Related Organizations
Campaign List
Introducing the Public Longevity Group: Building the Future of Public Trust
Building the first public sentiment analysis engine to unlock public trust in longevity.
- 104% Funded
- $104,395 Funded
- campaign
complete
Pearl: Participatory Evaluation of Aging with Rapamycin for Longevity
The first large-scale placebo-controlled clinical trial to determine the effects of Rapamycin on human longevity.
- 243% Funded
- $182,838 Funded
- campaign
complete
MitoMouse: SENS Transgenic Mouse Project
Creating a transgenic mouse demonstrating the rescue of Mitochondrial DNA mutations in mammals. We will express the mitochondrial ATP8 gene from the nucleus as...
- 155% Funded
- $77,625 Funded
- campaign
complete
Can NMN Increase Longevity?
The first long-term lifespan study in mice involving supplementation with NMN, a precursor of NAD+ metabolism, which has been shown to reduce aging markers and...
- 250% Funded
- $75,285 Funded
- campaign
complete
MouseAge: Visual Biomarker for Mouse Aging
Using AI and Computer Vision Techniques to Determine Age and Assess the Effect of Therapies Against Aging in Mice, Increasing the Pace of Research.
- 130% Funded
- $19,508 Funded
- campaign
complete
AgeMeter: Functional Age Biomarkers
Developing a diagnostic system to measure human functional age in comparison to chronological age, and assist in the assessment of anti-aging therapeutics.
- 100% Funded
- $30,061 Funded
- campaign
complete
CellAge: Targeting Senescent Cells With Synthetic Biology
Designing better systems for detection and safe removal of dysfunctional “senescent” cells to improve health and treat age-related diseases.
- 171% Funded
- $34,215 Funded
- campaign
complete
OncoSENS Control ALT Delete Cancer
High-throughput screening of a library of diverse drugs to find treatments for ‘ALT’ cancers, those which rely on Alternative Lengthening of Telomeres.
- 120% Funded
- $72,002 Funded
- campaign
complete
The Major Mouse Testing Program
Testing a new class of compounds, Senolytics, on their ability to extend healthy lifespan by clearing out dysfunctional cells in the body.
- 115% Funded
- $52,075 Funded
- campaign
complete
Articles from this author
March 27, 2026
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial in patients with plaque psoriasis, atopic dermatitis, and skin aging (photo-aged skin). The recently completed Phase 1 clinical trial, conducted in the...
March 27, 2026
Scientists used red blood cells as membrane donors to encapsulate healthy mitochondria and send them into diseased cells, achieving improvements across multiple models and conditions [1]. The delivery problem Mitochondrial diseases are a diverse group of disorders that arise when mitochondria malfunction. They are often caused by mutations in mitochondrial DNA (mtDNA) itself or in...
March 26, 2026
Cellular senescence, a state in which cells stop dividing but resist dying, accumulating in tissues over time, has emerged as one of the most promising targets in longevity medicine. Senescent cells actually serve important roles in development, wound healing, and cancer prevention, but as they accumulate with age or pathology, they become harmful: they secrete...
March 25, 2026
A new study identified two polyunsaturated fatty acids, α-eleostearic acid (α-ESA) and α-ESA methyl ester (α-ESA-me), that showed senolytic activity in cell cultures and a mouse model [1]. An anti-aging strategy Cellular senescence is one of the most critical aging-related processes. Senescent cells, which accumulate with age, are arrested in the cell cycle and are resistant...
March 24, 2026
BioAge Labs, Inc. ("BioAge”, "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today provided financial results for the full year ended December 31, 2025 and business updates for the fourth quarter ended December 31, 2025. "The past few months have been a defining...
March 24, 2026
In a new study, an ingenious CRISPR-based tool was used to create CAR T cells in vivo instead of the usual in vitro approach. It showed higher efficacy across three cancer types, including a solid tumor [1]. CAR T therapies: promising but imperfect Ideally, T cells, the killer cells of our adaptive immune systems, should...